Orthocell Remplir Sales Hit Record in US
Orthocell's nerve repair product Remplir posted its strongest U.S. sales month since launch in October.
Updated on Nov. 2, 2026 in Healthcare
Orthocell sold 92 Remplir units in the United States in October, generating A$279,000 in revenue. The result was 84% above the average monthly volume of 50 units recorded in the first quarter of FY27.
Why it matters
The company attributed the increase to repeat use by surgeons, a broader base of active distributor representatives and growing hospital access across key U.S. markets. Expanded manufacturing capacity signals the company expects demand to keep rising.
October's 92 units and A$279,000 in revenue were 84% above the 50-unit monthly average of the first quarter of FY27. Whether this level of volume holds beyond a single strong month has not been established.
The players
Orthocell
An Australian medical technology company that develops and commercializes the nerve repair product Remplir, and which is expanding its manufacturing capacity.
Device Technologies Group
A distributor that represents Remplir in Australia, New Zealand and Singapore.
The details
Orthocell has been expanding market access for Remplir as surgeons gain familiarity with the product, and hospitals are moving through Value Assessment Committee approval processes. The product is distributed in Australia, New Zealand and Singapore by Device Technologies Group and holds regulatory approvals in seven jurisdictions including the United States, Canada and Hong Kong.
Timeline
First quarter of FY27: average monthly U.S. volume of 50 Remplir units.
October 2026: 92 Remplir units sold, the strongest U.S. month since launch.
Market Landscape
Remplir's U.S. sales growth reflects a product moving from clearance into routine surgical use, a path that depends on hospitals completing their formulary approvals. The company's decision to expand manufacturing indicates it is positioning supply ahead of that adoption curve.
For surgeons and hospitals, expanded Remplir availability in the U.S. could widen access to this nerve repair option as approval processes conclude. Patients whose procedures involve the product would see the effect only where their hospital adopts it.
The takeaway
Strong single-month sales can signal momentum, but sustained hospital adoption is the measure that will show whether Remplir's U.S. growth holds.
Further reading
Explore more Healthcare coverage for the medical device market context behind this sales result.
